Lixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors

World News: . []

EAST SETAUKET NY May 15 2019 GLOBE NEWSWIRE -- Lixte Biotechnology LINK  Inc announced the opening of a pharmacologic study of the LINK  of its lead clinical compound LINK  to enter the brain and penetrate recurrent glioblastoma multifo...

More news and information about Lixte Biotechnology Holdings, Inc.

Published By:

Globe Newswire: 14:35 GMT Wednesday 15th May 2019

Published: .

Search for other references to "lixte" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us